Author index*

A

Abramowitz W (*see* Periclou et al). 2006;79:134-43
Adam U (*see* Oswald et al). 2006;79:206-17
Aklillu E (*see* Sim et al). 2006;79:103-13
Alexandre J (*see* Tran et al). 2006;79:570-80
Allen A (*see* Katz et al). 2006;79:186-96
Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. 2006;79:291-302
Arnold KA (*see* Igel et al). 2006;79:419-26
Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H_2 synthases. 2006;79:9-19 (Commentary)
Åsberg A (*see* Hermann et al). 2006;79:532-9
Avorn J (*see* Schneeweiss et al). 2006;79:379-88
Avram MJ (*see* Nitsun et al). 2006;79:549-57
Azizi M, Bissery A, Peyrard S, Guyene TT, Ozoux M-L, Floch A, Ménard J. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. 2006;79:49-61

B

Backman JT (*see* Kajosaari et al). 2006;79:213-42
Beaune P (*see* Pickering et al). 2006;79:371-8
Beaussier M (*see* Coulbault et al). 2006;79:316-24
Becquemont L (*see* Coulbault et al). 2006;79:316-24
Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Verstuyft C, Eichelbaum M, Fromm MF. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. 2006;79:449-60
Benowitz N (*see* Lerman et al). 2006;79:600-8
Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P, III. Female sex and oral contraceptive use accelerate nicotine metabolism. 2006;79:480-8
Bergmann K (*see* Igel et al). 2006;79:419-26
Bertilsson L (*see* Sim et al). 2006;79:103-13
Bertino JS, Jr. (*see* Chung et al). 2006;79:350-61
Bissery A (*see* Azizi et al). 2006;79:49-61
Björnsson E. Drug-induced liver injury: Hy's rule revisited. 2006;79:521-8 (Commentary)
Boer A (*see* Schalekamp et al). 2006;79:511-20 (Commentary)
Bogsrud MP (*see* Hermann et al). 2006;79:532-9
Boink GJJ (*see* Schalekamp et al). 2006;79:511-20 (Commentary)
Boos CJ, Goon PKY, Lip GYH. The endothelium, inflammation, and coagulation in sepsis. 2006;79:20-2 (Commentary)
Bosch TM (*see* Toornvliet et al). 2006;79:540-8
Boutaud O (*see* Aronoff et al). 2006;79:9-19 (Commentary)
Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. 2006;79:165-72 (Commentary)
Brockmöller J (*see* Lötsch et al). 2006;79:72-89
Burk O (*see* Becquemont et al). 2006;79:449-60

C

Canning C (*see* Schneeweiss et al). 2006;79:379-88
Carr R (*see* Katz et al). 2006;79:186-96
Cascorbi I (*see* Oswald et al). 2006;79:206-17
Cesano A (*see* Zia-Amirhosseini et al). 2006;79:558-69
Cheng C (*see* Lamba et al). 2006;79:325-38
Chirico MJ (*see* Aquilante et al). 2006;79:291-302
Chong P-Y (*see* Lee et al). 2006;79:197-205
Christensen M (*see* Sim et al). 2006;79:103-13
Chung E, Nafziger AN, Kazierad DJ, Bertino JS, Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. 2006;79:350-61
Coulbault L, Beaussier M, Verstuyft C, Weickmans H, Dubert L, Trégouet D, Descot C, Parc Y, Lienhart A, Jaillon P, Becquemont L. Environmental and genetic factors associated with morphine response in the postoperative period. 2006;79:316-24
Court MH (*see* Culm-Merdek et al). 2006;79:243-54
Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. 2006;79:243-54

D

Dahl M-L (*see* Sim et al). 2006;79:103-13
Danilenko DM (*see* Zia-Amirhosseini et al). 2006;79:558-69
Dawson EP (*see* Kurnik et al). 2006;79:173-85
Dazert E (*see* Oswald et al). 2006;79:206-17
Dazert P (*see* Meisel et al). 2006;79:62-71
de Hoon JNJM (*see* Vanmolkot et al). 2006;79:263-73
Deng C-Y (*see* Yu et al). 2006;79:581-9
Descot C (*see* Coulbault et al). 2006;79:316-24
Diedrich A (*see* Heusser et al). 2006;79:500-8
Dieras V (*see* Tran et al). 2006;79:570-80
Dionne RA (*see* Lee et al). 2006;79:407-18
Dionne RA (*see* Wang et al). 2006;79:303-15
Doan T (*see* Katz et al). 2006;79:186-96
Dormuth CR (*see* Schneeweiss et al). 2006;79:379-88
Drescher S (*see* Becquemont et al). 2006;79:449-60
Dubert L (*see* Coulbault et al). 2006;79:316-24
Dubray C (*see* Pickering et al). 2006;79:371-8
Ducharme MP (*see* Grenier et al). 2006;79:255-62

E

Edeki T (*see* Katz et al). 2006;79:186-96
Eichelbaum M (*see* Becquemont et al). 2006;79:449-60
Eichelbaum M (*see* Igel et al). 2006;79:419-26
Eliasson E (*see* Lundblad et al). 2006;79:287-8 (Letter)
Engeli S (*see* Heusser et al). 2006;79:500-8
Eschalier A (*see* Pickering et al). 2006;79:371-8

F

Figg WD. The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. 2006;79:1-8 (Commentary)
Firbas C (*see* Leitner et al). 2006;79:23-34
Floch A (*see* Azizi et al). 2006;79:49-61
Fradette C (*see* Grenier et al). 2006;79:255-62
Franssen EJF (*see* Toornvliet et al). 2006;79:540-8
Fricke C (*see* Oswald et al). 2006;79:206-17
Fromm MF (*see* Becquemont et al). 2006;79:449-60
Fujimura A (*see* Tsuruoka et al). 2006;79:389-96
Fujino A (*see* Maeda et al). 2006;79:427-39
Fujiwara H (*see* Maeda et al). 2006;79:427-39
Fukatsu S (*see* Masuda et al). 2006;79:90-102

*January, pp. 1-164; February, P1-P122; March, 165-290; April, 291-400; May, 401-510; June, 511-626. Index to the ASCPT meeting abstracts is located in the February issue.

G

Gan L (*see* Culm-Merdek et al). 2006;79:243-54
Gaston KL (*see* Aquilante et al). 2006;79:291-302
Geisslinger G (*see* Lötsch et al). 2006;79:35-48
Geisslinger G (*see* Lötsch et al). 2006;79:72-89
Geldof AA (*see* Toornvliet et al). 2006;79:540-8
Giebel J (*see* Meisel et al). 2006;79:62-71
Giessmann T (*see* Oswald et al). 2006;79:206-17
Girre V (*see* Tran et al). 2006;79:570-80
Glaeser H (*see* Becquemont et al). 2006;79:449-60
Glynn RJ (*see* Schneeweiss et al). 2006;79:379-88
Goh B-C (*see* Lee et al). 2006;79:197-205
Goldwasser F (*see* Tran et al). 2006;79:570-80
Goon PKY (*see* Boos et al). 2006;79:20-2 (Commentary)
Gorski JC (*see* Lemma et al). 2006;79:218-30
Goto M (*see* Masuda et al). 2006;79:90-102
Greenblatt DJ (*see* Culm-Merdek et al). 2006;79:243-54
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. 2006;79:125-33
Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. 2006;79:255-62
Grimm DR (*see* Katz et al). 2006;79:186-96
Guo J-Y (*see* Lee et al). 2006;79:197-205
Guyene TT (*see* Azizi et al). 2006;79:49-61

H

Haenisch S (*see* Oswald et al). 2006;79:206-17
Hagiwara T (*see* Seo et al). 2006;79:509-10 (Letter)
Hall SD (*see* Lemma et al). 2006;79:218-30
Halushka PV (*see* Halushka and Halushka). 2006;79:404-6 (Commentary)
Halushka MK, Halushka PV. Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypes. 2006;79:404-6 (Commentary)
Hamman MA (*see* Lemma et al). 2006;79:218-30
Han L (*see* Katz et al). 2006;79:186-96
Harmatz JS (*see* Culm-Merdek et al). 2006;79:243-54
Harmatz JS (*see* Greenblatt et al). 2006;79:125-33
Harris PA (*see* Kurnik et al). 2006;79:173-85
Hashimoto N (*see* Seo et al). 2006;79:509-10 (Letter)
Hauns B (*see* Westlind-Johnsson et al). 2006;79:339-49
Heinkele G (*see* Becquemont et al). 2006;79:449-60
Hermann M, Bogsrud MP, Molden E, Åsberg A, Mohebi BU, Ose L, Retterstøl K. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. 2006;79:532-9
Hermann R (*see* Westlind-Johnsson et al). 2006;79:339-49
Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Krüger N, Strauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. 2006;79:500-8
Hiatt WR (*see* Brass et al). 2006;79:165-72 (Commentary)
Hirano M (*see* Maeda et al). 2006;79:427-39
Hitzl M (*see* Becquemont et al). 2006;79:449-60
Hoffer C (*see* Lalovic et al). 2006;79:461-79
Hofmann U (*see* Becquemont et al). 2006;79:449-60
Hofmann U (*see* Igel et al). 2006;79:419-26
Hofmann U (*see* Lötsch et al). 2006;79:35-48
Holley-Shanks R (*see* Katz et al). 2006;79:186-96
Horan KA (*see* Culm-Merdek et al). 2006;79:243-54
Huennemeyer A (*see* Westlind-Johnsson et al). 2006;79:339-49

I

Ieiri I (*see* Maeda et al). 2006;79:427-39
Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, Bergmann K, Eichelbaum M, Kivistö KT. Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. 2006;79:419-26
Ihrie P (*see* Kurnik et al). 2006;79:173-85
Ingelman-Sundberg M (*see* Sim et al). 2006;79:103-13
Ingelman-Sundberg M (*see* Westlind-Johnsson et al). 2006;79:339-49
Inoue M (*see* Shimatani et al). 2006;79:144-52
Inui K (*see* Masuda et al). 2006;79:90-102
Ioka T (*see* Tsuruoka et al). 2006;79:389-96
Ishitsu T (*see* Seo et al). 2006;79:509-10 (Letter)

J

Jacob P, III (*see* Benowitz et al). 2006;79:480-8
Jaillon P (*see* Coulbault et al). 2006;79:316-24
Jedlitschky G (*see* Oswald et al). 2006;79:206-17
Jiang L (*see* Kurnik et al). 2006;79:173-85
Jilma B (*see* Leitner et al). 2006;79:23-34
Johansson P (*see* Lundblad et al). 2006;79:287-8 (Letter)
Johnson JA (*see* Aquilante et al). 2006;79:291-302
Jordan J (*see* Heusser et al). 2006;79:500-8
Jullien V (*see* Tran et al). 2006;79:570-80

K

Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. 2006;79:213-42
Kang D, Verotta D, Schwartz JB. Population analyses of amlodipine in patients living in the community and patients living in nursing homes. 2006;79:114-24
Kang D-K (*see* Park et al). 2006;79:590-9
Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. Organic anion transporting polypeptide 1B1 activity classified by *SLCO1B1* genotype influences atrasentan pharmacokinetics. 2006;79:186-96
Kazierad DJ (*see* Chung et al). 2006;79:350-61
Kharasch E (*see* Lalovic et al). 2006;79:461-79
Khor H-B (*see* Lee et al). 2006;79:197-205
Kim H (*see* Lee et al). 2006;79:407-18
Kim K-A (*see* Park et al). 2006;79:590-9
Kim RB (*see* Katz et al). 2006;79:186-96
Kitamura Y (*see* Maeda et al). 2006;79:427-39
Kiuchi T (*see* Masuda et al). 2006;79:90-102
Kivistö KT (*see* Igel et al). 2006;79:419-26
Klaua S (*see* Heusser et al). 2006;79:500-8
Klungel OH (*see* Schalekamp et al). 2006;79:511-20 (Commentary)
Kocher T (*see* Meisel et al). 2006;79:62-71
Kroemer HK (*see* Meisel et al). 2006;79:62-71
Kroemer HK (*see* Oswald et al). 2006;79:206-17
Krüger N (*see* Heusser et al). 2006;79:500-8
Kunert-Keil C (*see* Meisel et al). 2006;79:62-71
Kurnik D, Muszkat M, Li C, Sofowora GG, Solus J, Xie H-G, Harris PA, Jiang L, McMunn C, Ihrie P, Dawson EP, Williams SM, Wood AJJ, Stein CM. Variations in the α_{2A}-adrenergic receptor gene and their functional effects. 2006;79:173-85
Kuroiwa T (*see* Shimatani et al). 2006;79:144-52
Kusuhara H (*see* Maeda et al). 2006;79:427-39

L

Laaksonen R. On the mechanisms of statin-induced myopathy. 2006;79:529-31 (Commentary)
Lafolie P (*see* Lundblad et al). 2006;79:287-8 (Letter)
Lahu G (*see* Westlind-Johnsson et al). 2006;79:339-49
Laine K (*see* Saari et al). 2006;79:362-70
Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen L-Y, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. 2006;79:461-79
Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E. *MDR1* genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. 2006;79:325-38
Lamba V (*see* Lamba et al). 2006;79:325-38

Lammertsma AA (*see* Toornvliet et al). 2006;79:540-8
Lang L (*see* Marraffa et al). 2006;79:282-6
Langaee TY (*see* Aquilante et al). 2006;79:291-302
Leake B (*see* Katz et al). 2006;79:186-96
Lee O-J (*see* Park et al). 2006;79:590-9
Lee S-C, Ng S-S, Oldenburg J, Chong P-Y, Rost S, Guo J-Y, Yap H-L, Rankin SC, Khor H-B, Yeo T-C, Ng K-S, Soong R, Goh B-C. Interethnic variability of warfarin maintenance requirement is explained by *VKORC1* genotype in an Asian population. 2006;79:197-205
Lee Y-S (*see* Wang et al). 2006;79:303-15
Lee Y-S, Kim H, Wu T-X, Wang X-M, Dionne RA. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. 2006;79:407-18
Leese P (*see* Zia-Amirhosseini et al). 2006;79:558-69
Lehmann DF (*see* Marraffa et al). 2006;79:282-6
Leino K (*see* Saari et al). 2006;79:362-70
Leitner JM, Firbas C, Mayr FB, Reiter RA, Steinlechner B, Jilma B. Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. 2006;79:23-34
Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. 2006;79:218-30
Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. 2006;79:600-8
Lessov-Schlaggar CN (*see* Benowitz et al). 2006;79:480-8
Lewis RJ (*see* Brass et al). 2006;79:165-72 (Commentary)
Li C (*see* Kurnik et al). 2006;79:173-85
Libert F (*see* Pickering et al). 2006;79:371-8
Lienhart A (*see* Coulbault et al). 2006;79:316-24
Lin S-G (*see* Yu et al). 2006;79:581-9
Lin YS (*see* Lamba et al). 2006;79:325-38
Lip GYH (*see* Boos et al). 2006;79:20-2 (Commentary)
Lipicky R (*see* Brass et al). 2006;79:165-72 (Commentary)
Liu G-Z (*see* Yu et al). 2006;79:581-9
Liu K-H (*see* Park et al). 2006;79:590-9
Liu W (*see* Lamba et al). 2006;79:325-38
Liu-Chen L-Y (*see* Lalovic et al). 2006;79:461-79
Lopez LM (*see* Aquilante et al). 2006;79:291-302
Loriot M-A (*see* Pickering et al). 2006;79:371-8
Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. 2006;79:35-48
Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. 2006;79:72-89
Lubberink M (*see* Toornvliet et al). 2006;79:540-8
Luft FC (*see* Heusser et al). 2006;79:500-8
Lundblad MS, Ohlsson S, Johansson P, Lafolie P, Eliasson E. Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for *CYP2C9*3*. 2006;79:287-8 (Letter)
Luo Y (*see* Greenblatt et al). 2006;79:125-33
Luong L (*see* Nitsun et al). 2006;79:549-57
Lütjohann D (*see* Igel et al). 2006;79:419-26
Luurtsema G (*see* Toornvliet et al). 2006;79:540-8

M

Ma W-J (*see* Yu et al). 2006;79:581-9
Maclure M (*see* Schneeweiss et al). 2006;79:379-88
Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. 2006;79:427-39
Marraffa JM, Lang L, Ong G, Lehmann DF. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene. 2006;79:282-6
Martin SD (*see* Orlando et al). 2006;79:489-99
Masuda S, Goto M, Fukatsu S, Uesugi M, Ogura Y, Oike F, Kiuchi T, Takada Y, Tanaka K, Inui K. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. 2006;79:90-102
Mayr FB (*see* Leitner et al). 2006;79:23-34
McMunn C (*see* Kurnik et al). 2006;79:173-85
Meisel P, Giebel J, Kunert-Keil C, Dazert P, Kroemer HK, Kocher T. *MDR1* gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. 2006;79:62-71
Ménard J (*see* Azizi et al). 2006;79:49-61
Merritt GJ (*see* Grenier et al). 2006;79:255-62
Mieno H (*see* Shimatani et al). 2006;79:144-52
Mitchell A, Rushentsova U, Siffert W, Philipp T, Wenzel RR. The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism. 2006;79:274-81
Mohebi BU (*see* Hermann et al). 2006;79:532-9
Mohuczy D (*see* Aquilante et al). 2006;79:291-302
Molden E (*see* Hermann et al). 2006;79:532-9
Morelli G (*see* Grenier et al). 2006;79:255-62
Mueller T (*see* Katz et al). 2006;79:186-96
Murdter TE (*see* Becquemont et al). 2006;79:449-60
Murphy GS (*see* Nitsun et al). 2006;79:549-57
Murphy J (*see* Brass et al). 2006;79:165-72 (Commentary)
Muszkat M (*see* Kurnik et al). 2006;79:173-85

N

Nafziger AN (*see* Chung et al). 2006;79:350-61
Nakada N (*see* Seo et al). 2006;79:509-10 (Letter)
Nakagawa K (*see* Seo et al). 2006;79:509-10 (Letter)
Nakamura M (*see* Shimatani et al). 2006;79:144-52
Nassr N (*see* Westlind-Johnsson et al). 2006;79:339-49
Neuvonen PJ (*see* Kajosaari et al). 2006;79:213-42
Neuvonen PJ (*see* Saari et al). 2006;79:362-70
Ng K-S (*see* Lee et al). 2006;79:197-205
Ng S-S (*see* Lee et al). 2006;79:197-205
Niemi M (*see* Igel et al). 2006;79:419-26
Niemi M (*see* Kajosaari et al). 2006;79:213-42
Nitsun M, Szokol JW, Saleh HJ, Murphy GS, Vender JS, Luong L, Raikoff K, Avram MJ. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk. 2006;79:549-57

O

Oates JA (*see* Aronoff et al). 2006;79:9-19 (Commentary)
Oerlemans R (*see* Toornvliet et al). 2006;79:540-8
Oertel BG (*see* Lötsch et al). 2006;79:72-89
Ogura Y (*see* Masuda et al). 2006;79:90-102
Ohlsson S (*see* Lundblad et al). 2006;79:287-8 (Letter)
Oike F (*see* Masuda et al). 2006;79:90-102
Oldenburg J (*see* Lee et al). 2006;79:197-205
Olkkola KT (*see* Saari et al). 2006;79:362-70
Ong G (*see* Marraffa et al). 2006;79:282-6
Ookami H (*see* Tsuruoka et al). 2006;79:389-96
Orlando R, Padrini R, Perazzi M, Martin SD, Piccoli P, Palatini P. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine. 2006;79:489-99
Ose L (*see* Hermann et al). 2006;79:532-9
Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W. Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. 2006;79:206-17
Otsubo K (*see* Maeda et al). 2006;79:427-39
Ozoux M-L (*see* Azizi et al). 2006;79:49-61

P

Padrini R (*see* Orlando et al). 2006;79:489-99
Palatini P (*see* Orlando et al). 2006;79:489-99
Parc Y (*see* Coulbault et al). 2006;79:316-24
Park J-Y, Kim K-A, Park P-W, Lee O-J, Kang D-K, Shon J-H, Liu K-H, Shin J-G. Effect of *CYP3A5*3* genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. 2006;79:590-9
Park P-W (*see* Park et al). 2006;79:590-9
Patterson F (*see* Lerman et al). 2006;79:600-8
Perazzi M (*see* Orlando et al). 2006;79:489-99
Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. 2006;79:134-43
Perloff ES (*see* Greenblatt et al). 2006;79:125-33
Peyrard S (*see* Azizi et al). 2006;79:49-61
Philipp T (*see* Mitchell et al). 2006;79:274-81
Piccoli P (*see* Orlando et al). 2006;79:489-99
Pickering G, Loriot M-A, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. 2006;79:371-8
Pinto A (*see* Lerman et al). 2006;79:600-8
Pons G (*see* Tran et al). 2006;79:570-80

R

Rabillon F (*see* Tran et al). 2006;79:570-80
Raikoff K (*see* Nitsun et al). 2006;79:549-57
Rankin SC (*see* Lee et al). 2006;79:197-205
Rao N (*see* Periclou et al). 2006;79:134-43
Reiter RA (*see* Leitner et al). 2006;79:23-34
Remmler C (*see* Oswald et al). 2006;79:206-17
Retterstøl K (*see* Hermann et al). 2006;79:532-9
Rey E (*see* Tran et al). 2006;79:570-80
Reynolds R (*see* Culm-Merdek et al). 2006;79:243-54
Ring B (*see* Zia-Amirhosseini et al). 2006;79:558-69
Risinger C (*see* Sim et al). 2006;79:103-13
Risler L (*see* Lalovic et al). 2006;79:461-79
Rohrbacher M (*see* Lötsch et al). 2006;79:35-48
Rost S (*see* Lee et al). 2006;79:197-205
Rushentsova U (*see* Mitchell et al). 2006;79:274-81

S

Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. 2006;79:362-70
Sahelijo L (*see* Katz et al). 2006;79:186-96
Sakamoto K (*see* Tsuruoka et al). 2006;79:389-96
Saleh HJ (*see* Nitsun et al). 2006;79:549-57
Salfi M (*see* Zia-Amirhosseini et al). 2006;79:558-69
Schaefer C (*see* Becquemont et al). 2006;79:449-60
Schalekamp T, Boink GJJ, Visser LE, Stricker BHC, Boer A, Klungel OH. *CYP2C9* genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? 2006;79:511-20 (Commentary)
Schmidt H (*see* Lötsch et al). 2006;79:35-48
Schmidt H (*see* Lötsch et al). 2006;79:72-89
Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. 2006;79:379-88
Schuetz E (*see* Lamba et al). 2006;79:325-38
Schwab M (*see* Igel et al). 2006;79:419-26
Schwab M (*see* Lötsch et al). 2006;79:35-48
Schwartz JB. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. 2006;79:440-8
Schwartz JB (*see* Kang et al). 2006;79:114-24
Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K, Ishitsu T. Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy. 2006;79:509-10 (Letter)
Shen DD (*see* Lalovic et al). 2006;79:461-79
Shields PG (*see* Lerman et al). 2006;79:600-8
Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. 2006;79:144-52
Shin J-G (*see* Park et al). 2006;79:590-9
Shon J-H (*see* Park et al). 2006;79:590-9
Siegmund W (*see* Oswald et al). 2006;79:206-17
Siffert W (*see* Mitchell et al). 2006;79:274-81
Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. 2006;79:103-13
Simon N (*see* Becquemont et al). 2006;79:449-60
Skarke C (*see* Lötsch et al). 2006;79:35-48
Skarke C (*see* Lötsch et al). 2006;79:72-89
Sofowora GG (*see* Kurnik et al). 2006;79:173-85
Solus J (*see* Kurnik et al). 2006;79:173-85
Soong R (*see* Lee et al). 2006;79:197-205
Spear BB (*see* Katz et al). 2006;79:186-96
Stein CM. *Clinical Pharmacology & Therapeutics* annual report 2005. 2006;79:401-3 (Commentary)
Stein CM (*see* Kurnik et al). 2006;79:173-85
Steinlechner B (*see* Leitner et al). 2006;79:23-34
Stoffels G (*see* Heusser et al). 2006;79:500-8
Strauss A (*see* Heusser et al). 2006;79:500-8
Stricker BHC (*see* Schalekamp et al). 2006;79:511-20 (Commentary)
Strom S (*see* Lamba et al). 2006;79:325-38
Sudhop T (*see* Oswald et al). 2006;79:206-17
Sugiyama Y (*see* Maeda et al). 2006;79:427-39
Sullivan JT (*see* Zia-Amirhosseini et al). 2006;79:558-69
Swan GE (*see* Benowitz et al). 2006;79:480-8
Szokol JW (*see* Nitsun et al). 2006;79:549-57

T

Takada Y (*see* Masuda et al). 2006;79:90-102
Tanaka K (*see* Masuda et al). 2006;79:90-102
Tank J (*see* Heusser et al). 2006;79:500-8
Tazuma S (*see* Shimatani et al). 2006;79:144-52
Thummel KE (*see* Lamba et al). 2006;79:325-38
Toornvliet R, van Berckel BNM, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJF. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (*R*)-[^{11}C]verapamil and positron emission tomography. 2006;79:540-8
Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer JM. Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms. 2006;79:570-80
Trégouet D (*see* Coulbault et al). 2006;79:316-24
Tréluyer JM. 2006;79:570-80
Tromberg JS (*see* Aquilante et al). 2006;79:291-302
Tsuruoka S, Ioka T, Wakaumi M, Sakamoto K, Ookami H, Fujimura A. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. 2006;79:389-96
Tyndale R (*see* Lerman et al). 2006;79:600-8

U

Ueda N (*see* Seo et al). 2006;79:509-10 (Letter)
Uesugi M (*see* Masuda et al). 2006;79:90-102

V

Valtonen M (*see* Saari et al). 2006;79:362-70
van Berckel BNM (*see* Toornvliet et al). 2006;79:540-8
Van der Schueren BJEP (*see* Vanmolkot et al). 2006;79:263-73
Vanmolkot FHM, Van der Schueren BJEP, de Hoon JNJM. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by $CGRP_{8-37}$: evaluation of a human in vivo pharmacodynamic model. 2006;79:263-73

Vender JS (*see* Nitsun et al). 2006;79:549-57
Venkataramanan R (*see* Lamba et al). 2006;79:325-38
Ventura D (*see* Periclou et al). 2006;79:134-43
Verotta D (*see* Kang et al). 2006;79:114-24
Verstuyft C (*see* Becquemont et al). 2006;79:449-60
Verstuyft C (*see* Coulbault et al). 2006;79:316-24
Visser LE (*see* Schalekamp et al). 2006;79:511-20 (Commentary)
von Bergmann K (*see* Oswald et al). 2006;79:206-17
von Moltke LL (*see* Culm-Merdek et al). 2006;79:243-54
von Moltke LL (*see* Greenblatt et al). 2006;79:125-33
von Richter O (*see* Westlind-Johnsson et al). 2006;79:339-49
Vranderick M (*see* Grenier et al). 2006;79:255-62

W

Wacke W (*see* Oswald et al). 2006;79:206-17
Waddell CD (*see* Aquilante et al). 2006;79:291-302
Wakaumi M (*see* Tsuruoka et al). 2006;79:389-96
Wang PG (*see* Katz et al). 2006;79:186-96
Wang Q (*see* Katz et al). 2006;79:186-96
Wang X-M (*see* Lee et al). 2006;79:407-18
Wang X-M, Wu T-X, Lee Y-S, Dionne RA. Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: Implication for the adverse effects of cyclooxygenase-2 inhibitors. 2006; 79:303-15
Wang Z (*see* Lemma et al). 2006;79:218-30
Warzok R (*see* Oswald et al). 2006;79:206-17
Watanabe T (*see* Maeda et al). 2006;79:427-39
Watkins PB (*see* Lamba et al). 2006;79:325-38
Weickmans H (*see* Coulbault et al). 2006;79:316-24
Weitschies W (*see* Oswald et al). 2006;79:206-17
Wenzel RR (*see* Mitchell et al). 2006;79:274-81
Westlind-Johnsson A, Hermann R, Huennemeyer A, Hauns B, Lahu G, Nassr N, Zech K, Ingelman-Sundberg M, von Richter O. Identification and characterization of *CYP3A4*20*, a novel rare *CYP3A4* allele without functional activity. 2006;79:339-49
Wieting J (*see* Lötsch et al). 2006;79:72-89
Wileyto EP (*see* Lerman et al). 2006;79:600-8
Williams SM (*see* Kurnik et al). 2006;79:173-85
Wood AJJ (*see* Kurnik et al). 2006;79:173-85
Wu T-X (*see* Lee et al). 2006;79:407-18
Wu T-X (*see* Wang et al). 2006;79:303-15

X

Xie H-G (*see* Kurnik et al). 2006;79:173-85
Xiong H (*see* Katz et al). 2006;79:186-96
Xu J (*see* Shimatani et al). 2006;79:144-52

Y

Yap H-L (*see* Lee et al). 2006;79:197-205
Yarandi HN (*see* Aquilante et al). 2006;79:291-302
Yasuda K (*see* Maeda et al). 2006;79:427-39
Yates W (*see* Zia-Amirhosseini et al). 2006;79:558-69
Yeo T-C (*see* Lee et al). 2006;79:197-205
Yu H-M, Lin S-G, Liu G-Z, Zhang Y-Q, Ma W-J, Deng C-Y. Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. 2006;79:581-9

Z

Zaheer NA (*see* Lemma et al). 2006;79:218-30
Zech K (*see* Westlind-Johnsson et al). 2006;79:339-49
Zhang Y-Q (*see* Yu et al). 2006;79:581-9
Zia-Amirhosseini P, Salfi M, Leese P, Yates W, Danilenko DM, Ring B, Cesano A, Sullivan JT. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers. 2006;79:558-69
Zinny MA (*see* Greenblatt et al). 2006;79:125-33

Subject index*

A

Acenocoumarol
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? (Schalekamp et al). 2006;79:511-20 (Commentary)

Acetaminophen
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism (Pickering et al). 2006;79:371-8
Drug-induced liver injury: Hy's rule revisited (Björnsson). 2006;79:521-8 (Commentary)
New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H_2 synthases (Aronoff et al). 2006;79:9-19 (Commentary)
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene (Marraffa et al). 2006;79:282-6

Acid, gastric; *see* **Gastric acid**

Acid, mevalonic; *see* **Mevalonic acid**

Administration, cutaneous
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation (Lerman et al). 2006;79:600-8

Administration, oral
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam (Saari et al). 2006;79:362-70
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites (Lalovic et al). 2006;79:461-79

Age factors
Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[^{11}C]verapamil and positron emission tomography (Toornvliet et al). 2006;79:540-8
Population analyses of amlodipine in patients living in the community and patients living in nursing homes (Kang et al). 2006;79:114-24

Aged
Erythromycin breath test results in elderly, very elderly, and frail elderly persons (Schwartz). 2006;79:440-8

Aldosterone
Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors (Yu et al). 2006;79:581-9

Alleles
Identification and characterization of *CYP3A4*20*, a novel rare *CYP3A4* allele without functional activity (Westlind-Johnsson et al). 2006;79:339-49
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Alpha adrenergic receptors; *see* **Receptors, adrenergic, alpha**

Alprazolam
Effect of *CYP3A5*3* genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects (Park et al). 2006;79:590-9

Alzheimer's disease
Pharmacokinetic study of memantine in healthy and renally impaired subjects (Periclou et al). 2006;79:134-43

American Society for Clinical Pharmacology and Therapeutics
A message from the ASCPT membership committee chairperson (Sullivan). 2006;79:289-90, 397-400, 609-10

Amlodipine
Population analyses of amlodipine in patients living in the community and patients living in nursing homes (Kang et al). 2006;79:114-24

Analgesics
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism (Pickering et al). 2006;79:371-8
Environmental and genetic factors associated with morphine response in the postoperative period (Coulbault et al). 2006;79:316-24
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs (Lee et al). 2006;79:407-18
Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypes (Halushka and Halushka). 2006;79:404-6 (Commentary)

Androgens
The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer (Figg). 2006;79:1-8 (Commentary)

Anesthesia, general
Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57

Angiogenesis; *see* **Neovascularization**

Angiotensin-converting enzyme inhibitors
Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors (Yu et al). 2006;79:581-9
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (Azizi et al). 2006;79:49-61

Angiotensin receptors; *see* **Receptors, angiotensin**

Anions
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39
Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin (Igel et al). 2006;79:419-26
Organic anion transporting polypeptide 1B1 activity classified by *SLCO1B1* genotype influences atrasentan pharmacokinetics (Katz et al). 2006;79:186-96

Antidepressive agents
A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Sim et al). 2006;79:103-13

Antithrombins
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia (Leitner et al). 2006;79:23-34

Arrhythmia
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96

Asia
Interethnic variability of warfarin maintenance requirement is explained by *VKORC1* genotype in an Asian population (Lee et al). 2006;79:197-205

Atorvastatin
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy (Hermann et al). 2006;79:532-9
On the mechanisms of statin-induced myopathy (Laaksonen). 2006;79:529-31 (Commentary)

Atrasentan
Organic anion transporting polypeptide 1B1 activity classified by *SLCO1B1* genotype influences atrasentan pharmacokinetics (Katz et al). 2006;79:186-96

*January, pp. 1-164; February, pp. P1-P122; March, pp. 165-290; April, pp. 291-400; May, pp. 401-510; June, pp. 511-626. Index to the ASCPT meeting abstracts is located in the February issue.

AVE7688
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (Azizi et al). 2006;79:49-61

B

Beverages
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir (Culm-Merdek et al). 2006;79:243-54
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies (Greenblatt et al). 2006;79:125-33
Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans (Grenier et al). 2006;79:255-62
Bilirubin
Drug-induced liver injury: Hy's rule revisited (Björnsson). 2006;79:521-8 (Commentary)
Blood-brain barrier
Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[^{11}C]verapamil and positron emission tomography (Toornvliet et al). 2006;79:540-8
Blood coagulation
The endothelium, inflammation, and coagulation in sepsis (Boos et al). 2006;79:20-2 (Commentary)
Blood coagulation factors
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302
Bradycardia
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene (Marraffa et al). 2006;79:282-6
Breast feeding
Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57
Breath tests
Erythromycin breath test results in elderly, very elderly, and frail elderly persons (Schwartz). 2006;79:440-8

C

Calcitonin gene-related peptide
Calcitonin gene–related peptide–induced vasodilation in the human forearm is antagonized by $CGRP_{8-37}$: evaluation of a human in vivo pharmacodynamic model (Vanmolkot et al). 2006;79:263-73
Calcium channel blockers
MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists (Meisel et al). 2006;79:62-71
Carbamazepine
Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10 (Letter)
Cardiovascular system
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk (Brass et al). 2006;79:165-72 (Commentary)
Cations
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96
Celecoxib
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for *CYP2C9*3* (Lundblad et al). 2006;79:287-8 (Letter)
Central nervous system
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action (Lötsch et al). 2006;79:72-89
Cetirizine
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96
Cholesterol
Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17
Clinical Pharmacology & Therapeutics
Clinical Pharmacology & Therapeutics annual report 2005 (Stein). 2006;79:401-3 (Commentary)
Coagulation; *see* **Blood coagulation**
Codeine
Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites (Lötsch et al). 2006;79:35-48
Commentaries
Commentaries. 2006;79:1-22, 165-72, 401-6, 511-31
Contraceptives, oral
Female sex and oral contraceptive use accelerate nicotine metabolism (Benowitz et al). 2006;79:480-8
Corrections
Effect of a potent CYP3A inhibitor ketoconazole on interindividual variability of CYP3A activity as measured by oral midazolam (Bertino et al) (2006;79:P51). 2006;79:508
Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies (Jung and Reidenberg) (2005;77:324-34). 2006;79:510
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers (Hatsukami et al) (2005;78:456-67). 2006;79:396
Sex differences in CYP3A activity using intravenous and oral midazolam (Bertino et al) (2006;79:P66). 2006;79:508
Correspondence; *see* **Letters to the Editor**
Cost-benefit analysis
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? (Schalekamp et al). 2006;79:511-20 (Commentary)
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences (Schneeweiss et al). 2006;79:379-88
Cranberry juice; *see* **Beverages**
Cyclooxygenase inhibitors
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs (Lee et al). 2006;79:407-18
Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors (Wang et al). 2006;79:303-15
Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypes (Halushka and Halushka). 2006;79:404-6 (Commentary)
Cyclosporine
Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans (Grenier et al). 2006;79:255-62
Cytochrome P450
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for *CYP2C9*3* (Lundblad et al). 2006;79:287-8 (Letter)
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52
Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors (Yu et al). 2006;79:581-9
A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Sim et al). 2006;79:103-13
Comparison of midazolam and simvastatin as cytochrome P450 3A probes (Chung et al). 2006;79:350-61
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? (Schalekamp et al). 2006;79:511-20 (Commentary)

Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10 (Letter)
Effect of *CYP3A5*3* genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects (Park et al). 2006;79:590-9
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir (Culm-Merdek et al). 2006;79:243-54
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates (Lemma et al). 2006;79:218-30
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans (Becquemont et al). 2006;79:449-60
Identification and characterization of *CYP3A4*20*, a novel rare *CYP3A4* allele without functional activity (Westlind-Johnsson et al). 2006;79:339-49
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies (Greenblatt et al). 2006;79:125-33
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine (Orlando et al). 2006;79:489-99
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38
Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide (Kajosaari et al). 2006;79:231-42

D

Digoxin
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans (Becquemont et al). 2006;79:449-60
Docetaxel
Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80
Dose-response relationship, drug
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for *CYP2C9*3* (Lundblad et al). 2006;79:287-8 (Letter)
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? (Schalekamp et al). 2006;79:511-20 (Commentary)
Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin (Igel et al). 2006;79:419-26
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302
On the mechanisms of statin-induced myopathy (Laaksonen). 2006;79:529-31 (Commentary)
Pharmacokinetic study of memantine in healthy and renally impaired subjects (Periclou et al). 2006;79:134-43
Drug design
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk (Brass et al). 2006;79:165-72 (Commentary)
Drug interactions
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism (Pickering et al). 2006;79:371-8
A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Sim et al). 2006;79:103-13
Drug-induced liver injury: Hy's rule revisited (Björnsson). 2006;79:521-8 (Commentary)
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam (Saari et al). 2006;79:362-70
Erythromycin breath test results in elderly, very elderly, and frail elderly persons (Schwartz). 2006;79:440-8
Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites (Lötsch et al). 2006;79:35-48
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy (Hermann et al). 2006;79:532-9
Female sex and oral contraceptive use accelerate nicotine metabolism (Benowitz et al). 2006;79:480-8
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies (Greenblatt et al). 2006;79:125-33
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine (Orlando et al). 2006;79:489-99
New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H_2 synthases (Aronoff et al). 2006;79:9-19 (Commentary)
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia (Leitner et al). 2006;79:23-34
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96
Drug therapy
Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80

E

Economic consequences; *see* **Cost-benefit analysis**
Elderly; *see* **Aged**
Endothelins
The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81
Endothelium
The endothelium, inflammation, and coagulation in sepsis (Boos et al). 2006;79:20-2 (Commentary)
Endotoxins
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia (Leitner et al). 2006;79:23-34
Environment
Environmental and genetic factors associated with morphine response in the postoperative period (Coulbault et al). 2006;79:316-24
Epilepsy
Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10 (Letter)
Epoxy compounds
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302
Erythromycin
Erythromycin breath test results in elderly, very elderly, and frail elderly persons (Schwartz). 2006;79:440-8
Ethnic groups
Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10 (Letter)
Identification and characterization of *CYP3A4*20*, a novel rare *CYP3A4*

allele without functional activity (Westlind-Johnsson et al). 2006;79: 339-49

Interethnic variability of warfarin maintenance requirement is explained by *VKORC1* genotype in an Asian population (Lee et al). 2006;79:197-205

Excretion

Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96

Expression of genes; *see* **Gene expression**

Ezetimibe

Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17

F

Female gender; *see* **Sex**

Fentanyl

Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57

Fexofenadine

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates (Lemma et al). 2006;79:218-30

Fluconazole

Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies (Greenblatt et al). 2006;79: 125-33

Flurbiprofen

Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies (Greenblatt et al). 2006;79: 125-33

Fluvoxamine

Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine (Orlando et al). 2006;79:489-99

Forearm

Calcitonin gene–related peptide–induced vasodilation in the human forearm is antagonized by $CGRP_{8-37}$: evaluation of a human in vivo pharmacodynamic model (Vanmolkot et al). 2006;79:263-73

Frail elderly

Erythromycin breath test results in elderly, very elderly, and frail elderly persons (Schwartz). 2006;79:440-8

G

Gastric acid

Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

Gastroesophageal reflux

Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

Gender; *see* **Sex**

Gene expression

Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors (Wang et al). 2006;79:303-15

Genes

Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors (Yu et al). 2006;79:581-9

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302

Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006; 79:90-102

MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists (Meisel et al). 2006;79:62-71

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80

Variations in the α_{2A}-adrenergic receptor gene and their functional effects (Kurnik et al). 2006;79:173-85

Genetics

Environmental and genetic factors associated with morphine response in the postoperative period (Coulbault et al). 2006;79:316-24

Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs (Lee et al). 2006;79:407-18

Identification and characterization of *CYP3A4*20*, a novel rare *CYP3A4* allele without functional activity (Westlind-Johnsson et al). 2006;79: 339-49

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action (Lötsch et al). 2006;79:72-89

Genotype

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? (Schalekamp et al). 2006;79:511-20 (Commentary)

Effect of *CYP3A5*3* genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects (Park et al). 2006;79:590-9

Interethnic variability of warfarin maintenance requirement is explained by *VKORC1* genotype in an Asian population (Lee et al). 2006;79:197-205

Organic anion transporting polypeptide 1B1 activity classified by *SLCO1B1* genotype influences atrasentan pharmacokinetics (Katz et al). 2006;79:186-96

Gingival hyperplasia

MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists (Meisel et al). 2006;79:62-71

Glucuronosyltransferase

Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17

Glutathione transferases

Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80

Glycoproteins

Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[^{11}C]verapamil and positron emission tomography (Toornvliet et al). 2006;79:540-8

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates (Lemma et al). 2006;79:218-30

Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans (Becquemont et al). 2006;79:449-60

Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Graft rejection

Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006; 79:90-102

Grape juice; *see* **Beverages**

GST; *see* **Glutathione transferases**

H

Haplotypes
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39
Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypes (Halushka and Halushka). 2006;79:404-6 (Commentary)
Variations in the α_{2A}-adrenergic receptor gene and their functional effects (Kurnik et al). 2006;79:173-85

Hematologic diseases
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers (Zia-Amirhosseini et al). 2006;79:558-69

Heparin
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia (Leitner et al). 2006;79:23-34

Homozygote
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for *CYP2C9*3* (Lundblad et al). 2006;79:287-8 (Letter)
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

Human breast milk; *see* **Milk, human**

Hypertension
Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors (Yu et al). 2006;79:581-9

I

Inflammation
The endothelium, inflammation, and coagulation in sepsis (Boos et al). 2006;79:20-2 (Commentary)

Injections, intravenous
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam (Saari et al). 2006;79:362-70

Insurance benefits
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences (Schneeweiss et al). 2006;79:379-88

Interactions, drug; *see* **Drug interactions**

Interleukin-6
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia (Leitner et al). 2006;79:23-34

Intestines
Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006;79:90-102

Irbesartan
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (Azizi et al). 2006;79:49-61

J

Japan
Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10 (Letter)

K

Kidney diseases
Pharmacokinetic study of memantine in healthy and renally impaired subjects (Periclou et al). 2006;79:134-43

Kidney failure
Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96

L

Lactones
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy (Hermann et al). 2006;79:532-9

Lansoprazole
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

Leon I. Goldberg Young Investigator Award Lecture
The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer (Figg). 2006;79:1-8 (Commentary)

Letters to the Editor
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for *CYP2C9*3* (Lundblad et al). 2006;79:287-8
Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10

Leukocytes
Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[^{11}C]verapamil and positron emission tomography (Toornvliet et al). 2006;79:540-8

Levomethadone
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action (Lötsch et al). 2006;79:72-89

Lipids
Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin (Igel et al). 2006;79:419-26

Liver
Drug-induced liver injury: Hy's rule revisited (Björnsson). 2006;79:521-8 (Commentary)
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Liver function tests
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine (Orlando et al). 2006;79:489-99

Liver transplantation
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006;79:90-102

Living donors; *see* **Tissue donors**

M

Maintenance
Interethnic variability of warfarin maintenance requirement is explained by *VKORC1* genotype in an Asian population (Lee et al). 2006;79:197-205

MDR1; *see* **Genes**

Memantine
Pharmacokinetic study of memantine in healthy and renally impaired subjects (Periclou et al). 2006;79:134-43

Metabolism
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52
A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Sim et al). 2006;79:103-13

Female sex and oral contraceptive use accelerate nicotine metabolism (Benowitz et al). 2006;79:480-8
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine (Orlando et al). 2006;79:489-99
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action (Lötsch et al). 2006;79:72-89

Metalloproteinases
Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors (Wang et al). 2006;79:303-15

Metoprolol
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene (Marraffa et al). 2006;79:282-6

Mevalonic acid
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy (Hermann et al). 2006;79:532-9

Microcirculation
The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81

Midazolam
Comparison of midazolam and simvastatin as cytochrome P450 3A probes (Chung et al). 2006;79:350-61
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans (Becquemont et al). 2006;79:449-60
Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57

Milk, human
Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57

Montelukast
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide (Kajosaari et al). 2006;79:231-42

Morbidity
Population analyses of amlodipine in patients living in the community and patients living in nursing homes (Kang et al). 2006;79:114-24

Morphine
Environmental and genetic factors associated with morphine response in the postoperative period (Coulbault et al). 2006;79:316-24
Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites (Lötsch et al). 2006;79:35-48

Multidrug resistance associated protein; *see* **Proteins**

Muscles
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy (Hermann et al). 2006;79:532-9
On the mechanisms of statin-induced myopathy (Laaksonen). 2006;79:529-31 (Commentary)

N

Narcotics
Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites (Lötsch et al). 2006;79:35-48
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites (Lalovic et al). 2006;79:461-79

Neovascularization
The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer (Figg). 2006;79:1-8 (Commentary)

Nicotine
Female sex and oral contraceptive use accelerate nicotine metabolism (Benowitz et al). 2006;79:480-8
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation (Lerman et al). 2006;79:600-8

Nursing homes
Population analyses of amlodipine in patients living in the community and patients living in nursing homes (Kang et al). 2006;79:114-24

O

Obesity
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects (Heusser et al). 2006;79:500-8

Omeprazole
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

Opioids; *see* **Narcotics**

Oral administration; *see* **Administration, oral**

Oral contraceptives; *see* **Contraceptives, oral**

Oxycodone
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites (Lalovic et al). 2006;79:461-79

P

Palifermin
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers (Zia-Amirhosseini et al). 2006;79:558-69

Peptides
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39
Organic anion transporting polypeptide 1B1 activity classified by *SLCO1B1* genotype influences atrasentan pharmacokinetics (Katz et al). 2006;79:186-96

Pharmacodynamics
Calcitonin gene–related peptide–induced vasodilation in the human forearm is antagonized by $CGRP_{8-37}$: evaluation of a human in vivo pharmacodynamic model (Vanmolkot et al). 2006;79:263-73
Effect of *CYP3A5*3* genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects (Park et al). 2006;79:590-9
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam (Saari et al). 2006;79:362-70
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers (Zia-Amirhosseini et al). 2006;79:558-69
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites (Lalovic et al). 2006;79:461-79
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (Azizi et al). 2006;79:49-61

Pharmacokinetics
Effect of *CYP3A5*3* genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects (Park et al). 2006;79:590-9
Effect of *CYP3A5*3* on carbamazepine pharmacokinetics in Japanese patients with epilepsy (Seo et al). 2006;79:509-10 (Letter)
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam (Saari et al). 2006;79:362-70
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans (Becquemont et al). 2006;79:449-60
Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-

lowering efficacy of multiple-dose pravastatin (Igel et al). 2006;79: 419-26

Organic anion transporting polypeptide 1B1 activity classified by *SLCO1B1* genotype influences atrasentan pharmacokinetics (Katz et al). 2006;79:186-96

Pharmacokinetic study of memantine in healthy and renally impaired subjects (Periclou et al). 2006;79:134-43

Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers (Zia-Amirhosseini et al). 2006;79: 558-69

Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites (Lalovic et al). 2006;79:461-79

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (Azizi et al). 2006;79:49-61

Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80

Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans (Grenier et al). 2006;79:255-62

Phenotype

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Pilsicainide

Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96

Plasma

Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide (Kajosaari et al). 2006;79:231-42

Polymorphism

The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81

Associations between *CYP11B2* gene polymorphisms and the response to angiotensin-converting enzyme inhibitors (Yu et al). 2006;79:581-9

Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin (Igel et al). 2006;79: 419-26

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302

MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists (Meisel et al). 2006;79:62-71

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action (Lötsch et al). 2006;79:72-89

Pharmacokinetics and toxicity of docetaxel: role of *CYP3A*, *MDR1*, and *GST* polymorphisms (Tran et al). 2006;79:570-80

Polypeptides; *see* **Peptides**

Pomelo juice; *see* **Beverages**

Postoperative period

Environmental and genetic factors associated with morphine response in the postoperative period (Coulbault et al). 2006;79:316-24

Pravastatin

Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39

Impact of the *SLCO1B1* polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin (Igel et al). 2006;79: 419-26

Predictive value of tests

Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation (Lerman et al). 2006;79:600-8

Pregnanes

MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype (Lamba et al). 2006;79:325-38

Propofol

Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk (Nitsun et al). 2006;79:549-57

Propoxyphene

Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene (Marraffa et al). 2006;79:282-6

Prostaglandin antagonists

New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H_2 synthases (Aronoff et al). 2006;79:9-19 (Commentary)

Prostaglandin-endoperoxide synthase

New insights into the mechanism of action of acetaminophen: its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H_2 synthases (Aronoff et al). 2006;79:9-19 (Commentary)

Prostatic neoplasms

The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer (Figg). 2006;79:1-8 (Commentary)

Proteins

The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81

Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17

Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 (Tsuruoka et al). 2006;79:389-96

Proton pump

Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

A common novel *CYP2C19* gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (Sim et al). 2006;79:103-13

A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences (Schneeweiss et al). 2006;79:379-88

Publishing

Clinical Pharmacology & Therapeutics annual report 2005 (Stein). 2006; 79:401-3 (Commentary)

R

Rabeprazole

Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 (Shimatani et al). 2006;79:144-52

Ramipril

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans (Azizi et al). 2006;79:49-61

Receptors, adrenergic, alpha

Variations in the α_{2A}-adrenergic receptor gene and their functional effects (Kurnik et al). 2006;79:173-85

Receptors, angiotensin
The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81
Rejection, graft; *see* **Graft rejection**
Renal impairment; *see* **Kidney diseases**
Repaglinide
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide (Kajosaari et al). 2006;79:231-42
Risk factors
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006;79:90-102
MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists (Meisel et al). 2006;79:62-71
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk (Brass et al). 2006;79:165-72 (Commentary)
Ritonavir
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir (Culm-Merdek et al). 2006;79:243-54
Rofecoxib
Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors (Wang et al). 2006;79:303-15

S

Safety
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs (Lee et al). 2006;79:407-18
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers (Zia-Amirhosseini et al). 2006;79:558-69
Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk (Brass et al). 2006;79:165-72 (Commentary)
Septicemia
The endothelium, inflammation, and coagulation in sepsis (Boos et al). 2006;79:20-2 (Commentary)
Serotonergic system
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism (Pickering et al). 2006;79:371-8
Sex
Erythromycin breath test results in elderly, very elderly, and frail elderly persons (Schwartz). 2006;79:440-8
Female sex and oral contraceptive use accelerate nicotine metabolism (Benowitz et al). 2006;79:480-8
Population analyses of amlodipine in patients living in the community and patients living in nursing homes (Kang et al). 2006;79:114-24
Sibutramine
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects (Heusser et al). 2006;79:500-8
Simvastatin
Comparison of midazolam and simvastatin as cytochrome P450 3A probes (Chung et al). 2006;79:350-61
Skin
The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81
Smoking cessation
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation (Lerman et al). 2006;79:600-8
Statins
On the mechanisms of statin-induced myopathy (Laaksonen). 2006;79:529-31 (Commentary)
Surgery
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006;79:90-102
Sympathetic nervous system
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects (Heusser et al). 2006;79:500-8

T

Tacrolimus
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006;79:90-102
Tea
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies (Greenblatt et al). 2006;79:125-33
Telithromycin
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide (Kajosaari et al). 2006;79:231-42
Temocapril
Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39
Thalidomide
The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer (Figg). 2006;79:1-8 (Commentary)
Theophylline
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine (Orlando et al). 2006;79:489-99
Thrombin
Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia (Leitner et al). 2006;79:23-34
Tissue donors
Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients (Masuda et al). 2006;79:90-102
Tomography, emission-computed
Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[^{11}C]verapamil and positron emission tomography (Toornvliet et al). 2006;79:540-8
Transdermal administration; *see* **Administration, cutaneous**
Tropisetron
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism (Pickering et al). 2006;79:371-8

U

Uridine diphosphate
Intestinal expression of P-glycoprotein (*ABCB1*), multidrug resistance associated protein 2 (*ABCC2*), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans (Oswald et al). 2006;79:206-17
Ursodeoxycholic acid
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4–dependent pharmacokinetics in humans (Becquemont et al). 2006;79:449-60

V

Valsartan
The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo:

influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81

Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril (Maeda et al). 2006;79:427-39

Vasoconstriction

The angiotensin II receptor antagonist valsartan inhibits endothelin 1–induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein β_3 subunit (*GNB3*) C825T polymorphism (Mitchell et al). 2006;79:274-81

Vasodilation

Calcitonin gene–related peptide–induced vasodilation in the human forearm is antagonized by $CGRP_{8-37}$: evaluation of a human in vivo pharmacodynamic model (Vanmolkot et al). 2006;79:263-73

Vasomotor system

Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects (Heusser et al). 2006;79:500-8

Vasopeptidase inhibitors; *see* **Angiotensin-converting enzyme inhibitors**

Verapamil

Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[^{11}C]verapamil and positron emission tomography (Toornvliet et al). 2006;79:540-8

The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates (Lemma et al). 2006;79:218-30

Vitamin K

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302

Voriconazole

Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam (Saari et al). 2006;79:362-70

W

Warfarin

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? (Schalekamp et al). 2006;79:511-20 (Commentary)

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements (Aquilante et al). 2006;79:291-302

Interethnic variability of warfarin maintenance requirement is explained by *VKORC1* genotype in an Asian population (Lee et al). 2006;79:197-205